{
    "nct_id": "NCT03822845",
    "official_title": "Clinical Accuracy Assessment of 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence",
    "inclusion_criteria": "* Ability to understand and willingness to provide informed consent.\n* Pathologically proven prostate adenocarcinoma.\n* Rising PSA after definitive therapy with a prostatectomy or radiation therapy (external beam radiation therapy or brachytherapy).\n* If post-radical prostatectomy, a PSA level of > 0.2 ng/mL measured more than 6 weeks post-operatively with a second confirmatory persistent PSA > 0.2 ng/mL.\n* If post-radiation therapy, a PSA level that is equal to, or greater than, a 2 mg/mL rise above the lowest PSA value ('nadir').\n* A PSA level result within the last 2 months meeting criteria above.\n* Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an IND for initial efficacy investigations).\n* No other malignancy within the past 2 years (skin basal cell or cutaneous superficial squamous cell carcinoma or superficial bladder cancer are exempt from this criterion).\n* Karnofsky performance status greater than or equal to 50 (ECOG/WHO 0, 1, or 2) within the last 3 months.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Cannot receive furosemide.\n* History of Stevens-Johnson syndrome.\n* History or diagnosis of Paget's disease.\n* Malignancy other than current disease under study.\n* Allergy to sulfa or sulfa-containing medications.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",
    "miscellaneous_criteria": ""
}